I made a new thread for Nextcell because the introduction became quite long from the start. Things could have been packaged under the same TD1 thread if this had been noted in the original post, but in this discussion too, the focus has been on company-specific matters, not the industry in general.
Nextcell is, of course, quite a minuscule small company to deserve its own thread, so the readership will surely remain small. I prefer a little quality, rarely, over miscellaneous fluff.
Nextcell’s stem cell therapy is also considerably more generic compared to Diamyd, with a wide range of potential treatments, even though the initial focus is on TD1 treatment. I could later start delving into the mechanisms of action and the market for MSC treatments more generally.
https://keskustelut.inderes.fi/t/nextcell-kantasoluilla-kohti-mullistusta/64958/2